Mode
Text Size
Log in / Sign up
Phase 3 N=382 Randomized Quadruple-blind Treatment

Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery

Postoperative Pain

Enrolled (actual)
382
Serious AEs
0.8%
Results posted
Jan 2012
Primary outcome: Primary: Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours) — 34.8; 40.5 Scores on a scale — p=0.5265

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Tapentadol IR (Drug); Oxycodone IR (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)
34.8; 40.5 0.5265
SECONDARY
Summary of Kaplan-Meier Estimates for Time to Achieve 50% Reduction in Pain Intensity From Baseline
125.3; NA 0.7306
SECONDARY
Summary of Kaplan-Meier Estimates for Time to Achieve 30% Reduction in Pain Intensity From Baseline
73.9; 66.4 0.8524
SECONDARY
Summary of 30% Responder Rate (With Imputation) on Day 3
33.5; 34.4 0.9078
SECONDARY
Summary of 30% Responder Rate (With Imputation) on Day 7
48.1; 42.2 0.2633
SECONDARY
Summary of 50% Responder Rate (With Imputation) on Day 3
19.0; 22.7 0.4498
SECONDARY
Summary of 50% Responder Rate (With Imputation) on Day 7
35.4; 29.2 0.2158
SECONDARY
Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 2 Days (48 Hours)
10.6; 14.6 0.4811
SECONDARY
Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 7 Days
136.1; 122.1 0.7405
SECONDARY
Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 2 Days (48 Hours)
97.7; 92.0 0.3097
SECONDARY
Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 3 Days (72hours)
151.3; 140.9 0.2179
SECONDARY
Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 7 Days
299.1; 272.9 0.1051
SECONDARY
Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 2 Days (48 Hours)
108.2; 106.6 0.9367
SECONDARY
Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 3 Days (72 Hours)
186.1; 181.4 0.9441
SECONDARY
Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 7 Days
435.2; 395.0 0.3427
SECONDARY
Subject Satisfaction With Treatment
58.3; 48.1; 15.6; 20.4; 2.6; 5.5 0.1618
SECONDARY
Patient Global Impression of Change (PGIC) at End of Study
27.6; 26.0; 46.9; 42.5; 15.6; 13.3 0.0481 sig
SECONDARY
Clinician Global Impression of Change (CGIC) at End of Study
33.3; 29.3; 47.4; 39.8; 11.5; 12.7 0.0109 sig
SECONDARY
Summary of Medical Resource Utilization - Number of Calls by the Subject to Study Site Personnel
69; 74; 39; 28; 46; 70
SECONDARY
Summary of Medical Resource Utilization - Number of Other Types of Contacts With Healthcare Professionals
87; 89; 84; 85; 7; 6
SECONDARY
Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
34; 34; 20; 16; 104; 0
SECONDARY
Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
44; 23; 21; 14; 105; 3
SECONDARY
Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
9; 12; 8; 12; 42; 1
SECONDARY
Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
8; 14; 6; 14; 44; 2
SECONDARY
Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
27; 24; 17; 13; 81; 0
SECONDARY
Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
26; 17; 12; 20; 77; 2
SECONDARY
Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
23; 17; 13; 2; 56; 1
SECONDARY
Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
16; 15; 15; 9; 57; 2
SECONDARY
Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
35; 19; 8; 9; 71; 0
SECONDARY
Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
28; 23; 20; 8; 82; 3
SECONDARY
Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
3; 6; 3; 11; 23; 0
SECONDARY
Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
5; 3; 4; 12; 25; 1
SECONDARY
Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)
11; 7; 9; 11; 39; 1
SECONDARY
Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)
10; 6; 4; 6; 27; 1

Summary

The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.

Eligibility Criteria

Inclusion Criteria

  • Healthy on the basis of medical history and vital signs and meeting the American Society of Anesthesiology (ASA) physical status I, II, or III
  • completed screening procedures and have undergone one of the following elective outpatient arthroscopic surgical procedures: rotator cuff repair, labral tear repair, Bankart repair
  • an arthroscopic mini-open rotator cuff repair
  • (an arthroscopic distal clavicle resection performed in conjunction with a rotator cuff, labral tear or Bankart repair is also permitted)
  • received anesthesia administered to the shoulder by interscalene nerve block
  • receive study medication as the first oral analgesic medication following the orthopedic surgical procedure and expected to have moderate to severe pain requiring oral opioids for at least 3 days after surgery.

Exclusion Criteria

  • Patients whose post-operative pain would require non opioid analgesia as standard of care
  • received a non-allowed procedure
  • received intraoperative or post-operative anesthesia and/or analgesic medications which are expected to provide post-operative analgesia for >24 hours after discharge from the PACU (recovery room)
  • received intraoperatively >200 mg fentanyl or the morphine equivalent of another opioid (for the total procedure) or potent inhaled anesthesia (e.g., sevoflurane, isoflurane)
  • received IV PCA analgesia (intravenous pump the patient controls) in the PACU or a PACU stay >8 hours
  • expected to require inpatient treatment in a hospital or rehabilitation unit post operatively
  • anticipate any surgical procedure(s) within 7 days after the initial shoulder surgery
  • have significant nausea and/or vomiting at the time of randomization (patients may receive an anti-emetic prior to or during surgery)
  • received any of the following: long-acting or controlled-release opioids within 1-month prior to randomization
  • immediate release CII opioid formulations (e.g., Opana IR, Percocet, Percodan, oxycodone IR, Dilaudid) for >5 days total within 1 month before, and within 24 hours of, randomization
  • intra-articular (within a joint) or systemic steroids (except inhalers and topical steroids), within 1 month before randomization (exception, patients on a stable dose of chronic steroids for a minimum of 3 months, for a condition other than the shoulder pain)
  • use of non-steroidal anti-inflammatory drugs (NSAIDs) within 24-hours of randomization
  • have taken any CIII opioid formulation (e.g., Tylenol with Codeine) >3 days/week in the 1-month prior to randomization
  • treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake inhibitors (SNRIs) within 2 weeks before randomization
  • positive urine drug screen (cocaine, methadone, amphetamines, cannabinoids, opiates, benzodiazepines, barbiturates, and oxycodone)
  • have an active systemic or local infection
  • significant co-existing autoimmune inflammatory conditions
  • history of seizure disorder or epilepsy
  • presence of any of the following: mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm within 1 year of screening
  • severe traumatic brain injury, episode(s) of unconsciousness of more than 24 hours duration, or post-traumatic amnesia of more than 24 hours duration within 15 years of screening
  • known history of alcohol or drug abuse in the study doctor's judgment based on medical history
  • known or suspected to be opioid tolerant or dependent
  • known history of laboratory values reflecting severe kidney disease, known history of moderately or severely impaired liver function
  • history of allergy to, or hypersensitivity to tapentadol, oxycodone, or other components of the medication
  • history (within the past 6 months) of a major psychiatric disorder
  • history of suicidal ideation or suicidal attempts within the past 2 years
  • currently involved in litigation regarding their shoulder injury, have a disabi
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00814580). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search